AcelRx Pharmaceuticals Announces 20-For-1 Reverse Stock Split Effective Tomorrow, Oct. 26

Loading...
Loading...

AcelRx Pharmaceuticals, Inc. ACRX, (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it has filed a Certificate of Amendment to its Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of 1-for-20. The reverse stock split will become effective at 5:01 p.m. ET on Tuesday, October 25, 2022. AcelRx's common stock will continue to be traded on the Nasdaq Global Market under the symbol ACRX and will begin trading on a split-adjusted basis when the market opens on Wednesday, October 26, 2022. The reverse stock split is intended to enable AcelRx to regain compliance with the $1.00 minimum bid price required for continued listing on the Nasdaq Global Market. The new CUSIP number for AcelRx's common stock following the reverse stock split will be 00444T209.

Posted In: NewsStock Split
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...